Zobrazeno 1 - 10
of 98
pro vyhledávání: '"Moltó Abad M"'
Autor:
Pérez-López, J., Moltó-Abad, M., Muñoz-Delgado, C., Morales-Conejo, M., Ceberio-Hualde, L., del Toro, M.
Publikováno v:
In Molecular Genetics and Metabolism July 2018 124(3):216-227
Autor:
Pérez-López, J., Ceberio-Hualde, L., García-Morillo, J.S., Grau-Junyent, J.M., Hermida Ameijeiras, A., López-Rodríguez, M., Milisenda, J.C., Moltó Abad, M., Morales-Conejo, M., Nava Mateos, J.J.
Publikováno v:
In Molecular Genetics and Metabolism Reports March 2017 10:92-95
Autor:
Andrade F; Clinical Biochemistry, Drug Delivery and Therapy Group (CB-DDT), Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Bioingenería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto De Salud Carlos III, 08035 Barcelona, Spain.; Departament de Farmàcia i Tecnologia Farmacèutica i Fisicoquímica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), 08028 Barcelona, Spain., German-Cortés J; Clinical Biochemistry, Drug Delivery and Therapy Group (CB-DDT), Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Bioingenería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto De Salud Carlos III, 08035 Barcelona, Spain., Montero S; Clinical Biochemistry, Drug Delivery and Therapy Group (CB-DDT), Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Bioingenería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto De Salud Carlos III, 08035 Barcelona, Spain., Carcavilla P; Clinical Biochemistry, Drug Delivery and Therapy Group (CB-DDT), Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Bioingenería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto De Salud Carlos III, 08035 Barcelona, Spain., Baranda-Martínez-Abascal D; Clinical Biochemistry, Drug Delivery and Therapy Group (CB-DDT), Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Bioingenería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto De Salud Carlos III, 08035 Barcelona, Spain., Moltó-Abad M; Clinical Biochemistry, Drug Delivery and Therapy Group (CB-DDT), Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Bioingenería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto De Salud Carlos III, 08035 Barcelona, Spain.; Functional Validation & Preclinical Research (FVPR)/U20 ICTS Nanbiosis, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain., Seras-Franzoso J; Clinical Biochemistry, Drug Delivery and Therapy Group (CB-DDT), Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Bioingenería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto De Salud Carlos III, 08035 Barcelona, Spain.; Department of Genetics and Microbiology, Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Spain., Díaz-Riascos ZV; Clinical Biochemistry, Drug Delivery and Therapy Group (CB-DDT), Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Bioingenería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto De Salud Carlos III, 08035 Barcelona, Spain.; Functional Validation & Preclinical Research (FVPR)/U20 ICTS Nanbiosis, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain., Rafael D; Clinical Biochemistry, Drug Delivery and Therapy Group (CB-DDT), Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Bioingenería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto De Salud Carlos III, 08035 Barcelona, Spain.; Functional Validation & Preclinical Research (FVPR)/U20 ICTS Nanbiosis, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain., Abasolo I; Clinical Biochemistry, Drug Delivery and Therapy Group (CB-DDT), Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Bioingenería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto De Salud Carlos III, 08035 Barcelona, Spain.; Functional Validation & Preclinical Research (FVPR)/U20 ICTS Nanbiosis, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.; Clinical Biochemistry Service, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
Publikováno v:
Pharmaceutics [Pharmaceutics] 2023 Jun 08; Vol. 15 (6). Date of Electronic Publication: 2023 Jun 08.
Autor:
Carnicer-Cáceres C; Laboratory of Inborn Errors of Metabolism, Laboratoris Clínics, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain. Electronic address: clara.carnicer@vallhebron.cat., Villena-Ortiz Y; Laboratory of Inborn Errors of Metabolism, Laboratoris Clínics, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain. Electronic address: yolanda.villena@vallhebron.cat., Castillo-Ribelles L; Laboratory of Inborn Errors of Metabolism, Laboratoris Clínics, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain. Electronic address: laura.castillo@vallhebron.cat., Barquín-Del-Pino R; Laboratory of Inborn Errors of Metabolism, Laboratoris Clínics, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain. Electronic address: raquel.barquin@vallhebron.cat., Camprodon-Gomez M; Department of Internal Medicine, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain; Unit of Hereditary Metabolic Disorders, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain. Electronic address: maria.camprodon@vallhebron.cat., Felipe-Rucián A; Department of Pediatric Neurology, Unit of Hereditary Metabolic Disorders, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, 08035 Barcelona, Spain. Electronic address: ana.felipe@vallhebron.cat., Moreno-Martínez D; Department of Internal Medicine, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain; Unit of Hereditary Metabolic Disorders, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain. Electronic address: david.morenomartinez@nhs.net., Lucas-Del-Pozo S; Neurodegenerative Diseases Laboratory, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain; Department of Neurology, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain., Hernández-Vara J; Neurodegenerative Diseases Laboratory, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain; Department of Neurology, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain. Electronic address: jorge.hernandez@vallhebron.cat., García-Serra A; Neurodegenerative Diseases Laboratory, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain. Electronic address: anna.garcia@vhir.org., Tigri-Santiña A; Unit of Hereditary Metabolic Disorders, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain. Electronic address: atigri@vhebron.net., Moltó-Abad M; Functional Validation & Preclinical Research, Drug Delivery & Targeting Group, CIBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08035 Barcelona, Spain. Electronic address: marc.molto@vhir.org., Agraz-Pamplona I; Department of Nephrology, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain. Electronic address: irene.agraz@vallhebron.cat., Rodriguez-Palomares JF; Department of Cardiology, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain. Electronic address: josefernando.rodriguez@vallhebron.cat., Limeres-Freire J; Department of Cardiology, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain. Electronic address: javier.limeres@vallhebron.cat., Macaya-Font M; Laboratory of Inborn Errors of Metabolism, Laboratoris Clínics, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain. Electronic address: marc.macaya@vhebron.net., Rodríguez-Sureda V; Centre for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain; Biochemistry and Molecular Biology Research Centre for Nanomedicine, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain. Electronic address: virodriguez@clinic.cat., Miguel LD; Department of Pediatric Neurology, Unit of Hereditary Metabolic Disorders, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, 08035 Barcelona, Spain. Electronic address: lucy.dougherty@vhir.org., Del-Toro-Riera M; Unit of Hereditary Metabolic Disorders, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain; Department of Pediatric Neurology, Unit of Hereditary Metabolic Disorders, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, 08035 Barcelona, Spain. Electronic address: mireia.deltoro@vallhebron.cat., Pintos-Morell G; Unit of Hereditary Metabolic Disorders, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain; Functional Validation & Preclinical Research, Drug Delivery & Targeting Group, CIBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain. Electronic address: guillem.pintos@vhir.org., Arranz-Amo JA; Laboratory of Inborn Errors of Metabolism, Laboratoris Clínics, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain. Electronic address: joseantonio.arranz@vallhebron.cat.
Publikováno v:
Blood cells, molecules & diseases [Blood Cells Mol Dis] 2023 Jan; Vol. 98, pp. 102704. Date of Electronic Publication: 2022 Oct 05.
Autor:
Herrera, S, Pérez-López, J, Moltó-Abad, M, Güerri-Fernández, R, Cabezudo, E, Novelli, S, Esteve, J, Hernández, A, Roig, I, Solanich, X, Prieto-Alhambra, D, Nogués, X, Díez-Pérez, A
Publikováno v:
JOURNAL OF BONE AND MINERAL RESEARCH
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
BACKGROUND: Gaucher disease (GD), one of the commonest lysosomal disorders (a global population incidence of 1:50,000), is characterized by beta-glucocerebrosidase deficiency. Some studies have demonstrated bone infiltration in up to 80% of patients,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1a5f57173df9080e75a8e9677afb6542
http://ora.ox.ac.uk/objects/uuid:
http://ora.ox.ac.uk/objects/uuid:
Autor:
Quijada-Fraile P; Unidad de Enfermedades Mitocondriales y Enfermedades Metabólicas Hereditarias, Servicio de Pediatría, Hospital Universitario 12 de Octubre, CSUR Enfermedades Metabólicas, MetabERN, Instituto de Investigación Sanitaria Hospital 12 de octubre (imas12), CIBERER, Madrid, Spain. pilar.quijadaf@salud.madrid.org., Arranz Canales E; Servicio de Medicina Interna, CSUR Enfermedades Metabólicas, MetabERN, Instituto de Investigación Sanitaria Hospital 12 de octubre (imas12), Hospital Universitario 12 de Octubre, Madrid, Spain., Martín-Hernández E; Unidad de Enfermedades Mitocondriales y Enfermedades Metabólicas Hereditarias, Servicio de Pediatría, Hospital Universitario 12 de Octubre, CSUR Enfermedades Metabólicas, MetabERN, Instituto de Investigación Sanitaria Hospital 12 de octubre (imas12), CIBERER, Madrid, Spain., Ballesta-Martínez MJ; Sección de Genética Médica, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain.; CIBERER-ISCIII, Madrid, Spain., Guillén-Navarro E; Sección de Genética Médica, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain.; CIBERER-ISCIII, Madrid, Spain., Pintos-Morell G; Division of Rare Diseases, Reference Center for Hereditary Metabolic Disorders (CSUR, MetabERN, MetabXUEC), University Hospital Vall d'Hebron, Barcelona, Spain., Moltó-Abad M; Division of Rare Diseases, Reference Center for Hereditary Metabolic Disorders (CSUR, MetabERN, MetabXUEC), University Hospital Vall d'Hebron, Barcelona, Spain., Moreno-Martínez D; Division of Rare Diseases, Reference Center for Hereditary Metabolic Disorders (CSUR, MetabERN, MetabXUEC), University Hospital Vall d'Hebron, Barcelona, Spain.; Lysosomal Storage Disorders Unit, The Royal Free Hospital NHS Foundation Trust and University College London, London, UK., García Morillo S; Unidad de Enfermedades Autoinmunes y Minoritarias, Servicio de Medicina Interna, Hospital Virgen del Rocío, Sevilla, Spain., Blasco-Alonso J; Unidad de Gastroenterología y Nutrición Infantil, Grupo IBIMA Multidisciplinar Pediátrico, Hospital Regional Universitario de Málaga, Málaga, Spain., Couce ML; Unidad de Diagnóstico y Tratamiento de Enfermedades Metabólicas Hereditarias, Hospital Clínico Universitario de Santiago, IDIS, MetabERN, CIBERER, Santiago de Compostela, Spain., Gil Sánchez R; Hospital Universitario La Fe, Valencia, Spain., Cortès-Saladelafont E; Inborn Errors of Metabolism and Paediatric Neurology Unit, Paediatric Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain., López Rodríguez MA; Servicio de Medicina Interna, CSUR Enfermedades Metabólicas Hereditarias, Hospital Universitario Ramón y Cajal, Madrid, Spain., García-Silva MT; Unidad de Enfermedades Mitocondriales y Enfermedades Metabólicas Hereditarias, Servicio de Pediatría, Hospital Universitario 12 de Octubre, CSUR Enfermedades Metabólicas, MetabERN, Instituto de Investigación Sanitaria Hospital 12 de octubre (imas12), CIBERER, Madrid, Spain., Morales Conejo M; Servicio de Medicina Interna, CSUR Enfermedades Metabólicas, MetabERN, Instituto de Investigación Sanitaria Hospital 12 de octubre (imas12), Hospital Universitario 12 de Octubre, Madrid, Spain.
Publikováno v:
Orphanet journal of rare diseases [Orphanet J Rare Dis] 2021 Nov 03; Vol. 16 (1), pp. 464. Date of Electronic Publication: 2021 Nov 03.
Autor:
Abasolo I; Functional Validation & Preclinical Research, Drug Delivery & Targeting Group, CIBBIM-Nanomedicine, Vall d'Hebron Institut of Research (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain., Seras-Franzoso J; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain.; Drug Delivery & Targeting Group, CIBBIM-Nanomedicine, Vall d'Hebron Institut of Research (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain., Moltó-Abad M; Functional Validation & Preclinical Research, Drug Delivery & Targeting Group, CIBBIM-Nanomedicine, Vall d'Hebron Institut of Research (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain.; Division of Rare Diseases, Reference Center for Hereditary Metabolic Disorders (CSUR, XUEC, MetabERN, and CIBER-ER), Vall d'Hebron University Hospital, Barcelona, Spain., Díaz-Riascos V; Functional Validation & Preclinical Research, Drug Delivery & Targeting Group, CIBBIM-Nanomedicine, Vall d'Hebron Institut of Research (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain., Corchero JL; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain.; Institut de Biotecnologia i de Biomedicina (IBB) and Department of Genetics and Microbiology, Universitat Autònoma de Barcelona (UAB), Bellaterra, Barcelona, Spain., Pintos-Morell G; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain.; Drug Delivery & Targeting Group, CIBBIM-Nanomedicine, Vall d'Hebron Institut of Research (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.; Division of Rare Diseases, Reference Center for Hereditary Metabolic Disorders (CSUR, XUEC, MetabERN, and CIBER-ER), Vall d'Hebron University Hospital, Barcelona, Spain., Schwartz S Jr; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain.; Drug Delivery & Targeting Group, CIBBIM-Nanomedicine, Vall d'Hebron Institut of Research (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Publikováno v:
Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology [Wiley Interdiscip Rev Nanomed Nanobiotechnol] 2021 May; Vol. 13 (3), pp. e1684. Date of Electronic Publication: 2020 Dec 13.
Autor:
Carnicer-Cáceres C; Laboratory of Inborn Errors of Metabolism, Laboratoris Clínics, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain., Arranz-Amo JA; Laboratory of Inborn Errors of Metabolism, Laboratoris Clínics, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain., Cea-Arestin C; Laboratory of Inborn Errors of Metabolism, Laboratoris Clínics, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain., Camprodon-Gomez M; Department of Internal Medicine, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Unit of Hereditary Metabolic Disorders, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain., Moreno-Martinez D; Department of Internal Medicine, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Unit of Hereditary Metabolic Disorders, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Lysosomal Storage Disorders Unit, Royal Free Hospital NHS Foundation Trust and University College London, London WC1E 6BT, UK., Lucas-Del-Pozo S; Neurodegenerative Diseases Laboratory, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Department of Neurology, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK., Moltó-Abad M; Functional Validation & Preclinical Research, Drug Delivery & Targeting Group, CIBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08035 Barcelona, Spain., Tigri-Santiña A; Unit of Hereditary Metabolic Disorders, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain., Agraz-Pamplona I; Department of Nephrology, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain., Rodriguez-Palomares JF; Department of Cardiology, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain., Hernández-Vara J; Neurodegenerative Diseases Laboratory, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Department of Neurology, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain., Armengol-Bellapart M; Neurodegenerative Diseases Laboratory, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Department of Neurology, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain., Del-Toro-Riera M; Unit of Hereditary Metabolic Disorders, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Department of Pediatric Neurology, Unit of Hereditary Metabolic Disorders, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, 08035 Barcelona, Spain., Pintos-Morell G; Unit of Hereditary Metabolic Disorders, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Functional Validation & Preclinical Research, Drug Delivery & Targeting Group, CIBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.
Publikováno v:
Journal of clinical medicine [J Clin Med] 2021 Apr 13; Vol. 10 (8). Date of Electronic Publication: 2021 Apr 13.
Autor:
Gervas-Arruga, Javier1 (AUTHOR) javier.gervas@takeda.com, Barba-Romero, Miguel Ángel2,3 (AUTHOR) mabarbar@sescam.jccm.es, Fernández-Martín, Jorge Julián4 (AUTHOR) julianfernandezmartin58@gmail.com, Gómez-Cerezo, Jorge Francisco5,6 (AUTHOR) jfrancisco.gomez@salud.madrid.org, Segú-Vergés, Cristina7 (AUTHOR) cristina.segu@anaxomics.com, Ronzoni, Giacomo8 (AUTHOR) giacomo.ronzoni@takeda.com, Cebolla, Jorge J.8 (AUTHOR) jorge-javier.cebolla@takeda.com
Publikováno v:
International Journal of Molecular Sciences. Oct2024, Vol. 25 Issue 19, p10329. 18p.
Autor:
Seras-Franzoso J; Drug Delivery & Targeting CIBBIM-Nanomedicine Vall d'Hebron Institute of Research Universitat Autònoma de Barcelona Barcelona Spain.; Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-BBN) Barcelona Spain., Díaz-Riascos ZV; Drug Delivery & Targeting CIBBIM-Nanomedicine Vall d'Hebron Institute of Research Universitat Autònoma de Barcelona Barcelona Spain.; Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-BBN) Barcelona Spain.; Functional Validation & Preclinical Research (FVPR) CIBBIM-Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona Spain., Corchero JL; Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-BBN) Barcelona Spain.; Institut de Biotecnologia i de Biomedicina (IBB) and Department of Genetics and Microbiology Universitat Autònoma de Barcelona (UAB) Bellaterra Barcelona Spain., González P; Drug Delivery & Targeting CIBBIM-Nanomedicine Vall d'Hebron Institute of Research Universitat Autònoma de Barcelona Barcelona Spain.; Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-BBN) Barcelona Spain., García-Aranda N; Drug Delivery & Targeting CIBBIM-Nanomedicine Vall d'Hebron Institute of Research Universitat Autònoma de Barcelona Barcelona Spain.; Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-BBN) Barcelona Spain.; Functional Validation & Preclinical Research (FVPR) CIBBIM-Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona Spain., Mandaña M; Drug Delivery & Targeting CIBBIM-Nanomedicine Vall d'Hebron Institute of Research Universitat Autònoma de Barcelona Barcelona Spain.; Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-BBN) Barcelona Spain.; Functional Validation & Preclinical Research (FVPR) CIBBIM-Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona Spain., Riera R; Nanoscopy for Nanomedicine Group Institute for Bioengineering of Catalonia (IBEC) Barcelona Spain., Boullosa A; Drug Delivery & Targeting CIBBIM-Nanomedicine Vall d'Hebron Institute of Research Universitat Autònoma de Barcelona Barcelona Spain.; Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-BBN) Barcelona Spain.; Functional Validation & Preclinical Research (FVPR) CIBBIM-Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona Spain., Mancilla S; Drug Delivery & Targeting CIBBIM-Nanomedicine Vall d'Hebron Institute of Research Universitat Autònoma de Barcelona Barcelona Spain.; Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-BBN) Barcelona Spain.; Functional Validation & Preclinical Research (FVPR) CIBBIM-Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona Spain., Grayston A; Neurovascular Research Laboratory Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona Spain., Moltó-Abad M; Drug Delivery & Targeting CIBBIM-Nanomedicine Vall d'Hebron Institute of Research Universitat Autònoma de Barcelona Barcelona Spain.; Division of Rare Diseases Reference Center for Hereditary Metabolic Disorders (CSUR, XUEC, MetabERN, and CIBER-ER) Vall d'Hebron University Hospital Barcelona Spain., Garcia-Fruitós E; Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-BBN) Barcelona Spain.; Institut de Biotecnologia i de Biomedicina (IBB) and Department of Genetics and Microbiology Universitat Autònoma de Barcelona (UAB) Bellaterra Barcelona Spain., Mendoza R; Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-BBN) Barcelona Spain.; Institut de Biotecnologia i de Biomedicina (IBB) and Department of Genetics and Microbiology Universitat Autònoma de Barcelona (UAB) Bellaterra Barcelona Spain., Pintos-Morell G; Drug Delivery & Targeting CIBBIM-Nanomedicine Vall d'Hebron Institute of Research Universitat Autònoma de Barcelona Barcelona Spain.; Division of Rare Diseases Reference Center for Hereditary Metabolic Disorders (CSUR, XUEC, MetabERN, and CIBER-ER) Vall d'Hebron University Hospital Barcelona Spain., Albertazzi L; Nanoscopy for Nanomedicine Group Institute for Bioengineering of Catalonia (IBEC) Barcelona Spain., Rosell A; Neurovascular Research Laboratory Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona Spain., Casas J; RUBAM, Biological Chemistry Institute of Advanced Chemistry of Catalonia (IQAC-CSIC) Barcelona Spain.; Networking Research Center on Hepatic and Digestive Diseases (CIBEREHD) Barcelona Spain., Villaverde A; Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-BBN) Barcelona Spain.; Institut de Biotecnologia i de Biomedicina (IBB) and Department of Genetics and Microbiology Universitat Autònoma de Barcelona (UAB) Bellaterra Barcelona Spain., Schwartz S Jr; Drug Delivery & Targeting CIBBIM-Nanomedicine Vall d'Hebron Institute of Research Universitat Autònoma de Barcelona Barcelona Spain.; Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-BBN) Barcelona Spain., Abasolo I; Drug Delivery & Targeting CIBBIM-Nanomedicine Vall d'Hebron Institute of Research Universitat Autònoma de Barcelona Barcelona Spain.; Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-BBN) Barcelona Spain.; Functional Validation & Preclinical Research (FVPR) CIBBIM-Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona (UAB) Barcelona Spain.
Publikováno v:
Journal of extracellular vesicles [J Extracell Vesicles] 2021 Mar; Vol. 10 (5), pp. e12058. Date of Electronic Publication: 2021 Mar 12.